Dr. Burke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Northeast Medical Group/Yale New Haven Hospital
20 York Street. CB 2041
New Haven, CT 06510Phone+1 203-688-4748
Summary
- Dr. Leah Burke is an internist in New Haven, CT and is affiliated with multiple hospitals in the area, including Yale-New Haven Hospital and NewYork-Presbyterian/Weill Cornell. She received her medical degree from Boston University School of Medicine. She completed fellowship training in infectious diseases and is experienced in the development of clinical trials for patients with HIV and hepatitis C. She is an Assistant Clinical Professor at the Yale School of Medicine and an Associate Director of the Hospitalist service at Yale New Haven Hospital.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 2011 - 2014
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2007 - 2010
- Boston University School of MedicineClass of 2007
Certifications & Licensure
- CT State Medical License 2010 - 2025
- NY State Medical License 2012 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Vice Chair AIDS Clinical Trials Group (ACTG) Monoclonal Antibody Working Group, 2015
Clinical Trials
- A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Start of enrollment: 2014 Jan 01
- 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption Start of enrollment: 2015 Mar 11
- A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Start of enrollment: 2015 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 27 citationsThe complex relationship between cost and quality in US health care.Leah A. Burke, Andrew M. Ryan
The Virtual Mentor. 2014-02-01 - 588 citationsViraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Marina Caskey, Florian Klein, Julio C. C. Lorenzi, Michael S. Seaman, Anthony P. West
Nature. 2015-06-25 - 364 citationsHIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionJohannes F. Scheid, Joshua A. Horwitz, Yotam Bar-On, Edward F. Kreider, Ching-Lan Lu
Nature. 2016-07-28
Journal Articles
- Septic ArthritisCho HJ, Burke LA, Lee M, Hospital Medicine Clinics, 10/31/2014
Books/Book Chapters
Abstracts/Posters
- Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Virus Infection in Patients with Human Immunodeficiency Virus.Burke LA, Fierer DS, Cassagnol D, Hijdra R, Van Seggelen W, and Marks, KM, Infectious Diseases (ID) Week, San Francisco, CA, 10/5/2013
Lectures
- Hepatitis C in the Era of Direct Acting Antiviral Therapy (Grand Rounds)Department of Medicine Grand Rounds at North Shore-LIJ Forest Hills Hospital - 10/21/2015
Other
- Acute HCV Treatment in HIV-infected PatientsBurke LA, Marks K, IAS-USA Case on the Web
http://www.iasusa.org/content/treatment-acute-hepatitis-c-virus-infection-hiv-infected-patients
6/5/2015
Grant Support
- 3BNC117 mAb in HIV-infected Subjects on Combination ARTNIH/NIAID2015–2018
- Passive Immunotherapy with Human Anti-HIV Neutralizing Monoclonal AntibodiesBill and Melinda Gates Foundation2013–2017
- HIV Adherence Bottle Intervention Trial (HABIT)The Robert Mapplethorpe Foundation2015–2016
- HIV Adherence Bottle Intervention Trial (HABIT)Health 2.02014–2015
Committees
- Vice Chair, AIDS Clinical Trials Group Monoclonal Antibody Working Group 2015 - Present
- Vice Chair, AIDS Clinical Trials Group A5357 Protocol Development Team 2015 - Present
Research History
- InvestigatorInvestigator on multiple clinical trials evaluating the use of broadly-neutralizing monoclonal antibodies to treat and prevent HIV infection.2014 - Present
- Principal Investigator (HABIT Study)A phase 1 clinical trial, aimed at investigating whether a novel smart pill bottle will improve adherence to antiretroviral medication in patients with HIV, and whether a new laboratory test (tenofovir dried blood spots) will be a good assessment of antiretroviral medication compliance.2014 - 2018
Professional Memberships
- Member
- HIVMAMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: